Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease

被引:81
作者
Emery, S
Capra, WB
Cooper, DA
Mitsuyasu, RT
Kovacs, JA
Vig, P
Smolskis, M
Saravolatz, LD
Lane, HC
Fyfe, GA
Curtin, PT
机构
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2010, Australia
[2] Chiron Corp, Emeryville, CA 94608 USA
[3] Univ Calif Los Angeles, CARE Ctr, Los Angeles, CA USA
[4] NIH, Ctr Clin, Bethesda, MD 20892 USA
[5] NIAID, NIH, Bethesda, MD 20892 USA
[6] Henry Ford Hosp, Detroit, MI 48202 USA
关键词
D O I
10.1086/315736
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We collected human immunodeficiency virus (HIV) disease progression, survival, most recent CD4 cell count, and plasma HIV RNA levels from patients (n = 157) who participated in randomized clinical trials of interleukin (IL)-2 that commenced before 1995. Data were available for 155 (99%) patients. Statistical analyses were based on the intention-to-treat principle. Median follow-up was 28 months and 30 months for control and IL-2 patients, respectively. Twenty-five (16%) patients developed AIDS or died during follow-up (16 control patients vs. 9 IL-2 patients; R-2 = 0.57; P = .22). Mean change from baseline CD4 cell count was significantly higher in patients randomized to receive IL-2 (368 vs. 153 cells/mu L; P = .003). Mean change from baseline plasma HIV RNA was significantly lower in patients randomized to receive IL-2 (-0.98 vs. -0.63 log copies/mL; P = .004). Significant improvements in CD4 cell count and plasma HIV RNA in recipients of IL-2 relative to control patients were associated with a nonsignificant trend toward improved clinical outcome.
引用
收藏
页码:428 / 434
页数:7
相关论文
共 44 条
[1]   EXCELLENT SENSITIVITY AND SPECIFICITY OF HIV-1 CULTURES USING WHOLE-BLOOD [J].
ALIMENTI, A ;
SULLIVAN, JL ;
LEVY, J ;
LUZURIAGA, K .
AIDS, 1993, 7 (08) :1127-1127
[2]  
[Anonymous], 1996, Lancet, V348, P283
[3]  
[Anonymous], STAT ANAL FAILURE TI
[4]   Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load [J].
Arnó, A ;
Ruiz, L ;
Juan, M ;
Jou, A ;
Balagué, M ;
Zayat, MK ;
Marfil, S ;
Martínez-Picado, J ;
Martínez, MA ;
Romeu, J ;
Pujol-Borrell, R ;
Lane, C ;
Clotet, B .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :56-60
[5]   THE PRACTICE OF METAANALYSIS [J].
BAILAR, JC .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1995, 48 (01) :149-157
[6]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[7]   Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study [J].
Carr, A ;
Emery, S ;
Lloyd, A ;
Hoy, J ;
Garsia, R ;
French, M ;
Stewart, G ;
Fyfe, G ;
Cooper, DA .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (04) :992-999
[8]  
*CDCP, 1993, MMWR-MORBID MORTAL W, V41, P1
[9]  
Chaisson R E, 1995, Kekkaku, V70, P313
[10]   Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy [J].
Chun, TW ;
Engel, D ;
Mizell, SB ;
Hallahan, CW ;
Fischette, M ;
Park, S ;
Davey, RT ;
Dybul, M ;
Kovacs, JA ;
Metcalf, JA ;
Mican, JM ;
Berrey, MM ;
Corey, L ;
Lane, HC ;
Fauci, AS .
NATURE MEDICINE, 1999, 5 (06) :651-655